EGFR and non-small cell lung carcinoma: Osimertinib, an irreversible tyrosine kinase receptor inhibitor, is the standard treatment for previously untreated advanced NSCLC and as adjuvant therapy for patients with stage IB to IIIA NSCLC with EGFR Exon 19 deletions or EGFR Exon 21 L858R mutations, based on ADURA and FLAURA trials [12,13].